Artiva Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Artiva Biotherapeutics's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 92.1% per year.
Key information
-7.0%
Earnings growth rate
-2.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 92.1% |
| Return on equity | -128.5% |
| Net Margin | -111.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Artiva Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 29 | -33 | 13 | 48 |
| 31 Mar 24 | 33 | -26 | 14 | 47 |
| 31 Dec 23 | 33 | -29 | 14 | 50 |
| 31 Mar 23 | 5 | -63 | 21 | 49 |
| 31 Dec 22 | 5 | -59 | 21 | 44 |
| 31 Mar 22 | 3 | -41 | 14 | 30 |
| 31 Dec 21 | 2 | -72 | 13 | 42 |
| 30 Sep 21 | 1 | -66 | 10 | 38 |
| 31 Dec 20 | 0 | -18 | 4 | 14 |
Quality Earnings: ARTV is currently unprofitable.
Growing Profit Margin: ARTV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARTV is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare ARTV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ARTV has a negative Return on Equity (-128.48%), as it is currently unprofitable.